Skip to search formSkip to main contentSkip to account menu

SNX 2112

Known as: SNX-2112, SNX2112 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Heterocyclic Compounds, 4 or More Rings

Narrower (1)

PF 04928473

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats
Abstract 1. The promising anticancer agent SNX-2112 (a novel Hsp90 inhibitor) is poorly bioavailable after oral administration… 
2013
2013
Results of two phase I dose escalation studies of the oral heat shock protein 90 (Hsp90) inhibitor SNX-5422.
2617 Background: SNX-5422 is a prodrug of SNX-2112, a highly potent, non-geldanamycin analog, HSP90 inhibitor with preclinical… 
2012
2012
The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo.
SNX-2112 is a selective heat shock protein 90 (Hsp90) inhibitor which can exert a potent anticancer activity. In this… 
2012
2012
Anti‐tumor activity of the HSP90 inhibitor SNX‐2112 in pediatric cancer cell lines
HSP90 plays a central role in stabilizing client proteins involved in malignant processes. SNX‐2112 is an orally administered… 
2012
2012
The heat shock protein 90 inhibitor SNX-2112 inhibits B 16 melanoma cell growth in vitro and in vivo
SNX-2112 is a selective heat shock protein 90 (Hsp90) inhibitor which can exert a potent anticancer activity. In this study, we… 
2011
2011
Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition
Purpose: Heat shock protein-90 (HSP-90), a molecular chaperone required by numerous oncogenic kinases [e.g., HER-2, epidermal… 
2011
2011
Preclinical pharmacokinetic analysis of SNX-2112, a novel Hsp90 inhibitor, in rats.
  • Q. ZhaiG. Gong Y. Wang
  • Biomedicine & pharmacotherapy = Biomedecine…
  • 2011
  • Corpus ID: 25507005
2009
2009
Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
Inhibition of Hsp90 has emerged as a therapeutic strategy to target NSCLC subtypes, which are refractory to epidermal growth… 
2009
2009
Transcriptomic and proteomic approach to studying SNX‐2112‐induced K562 cells apoptosis and anti‐leukemia activity in K562‐NOD/SCID mice
2008
2008
A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422
14613 Background: SNX-5422 is an oral pro-drug of SNX-2112, a potent and highly selective small-molecule inhibitor of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)